BPC-157 is the most-searched research peptide and the one with the least human dosing data: no label, no dose-finding trial, one uncontrolled case series. Every dose figure in circulation therefore comes from an animal study, a clinic's protocol page or a vendor's guide. This page collects those figures, says which kind of source each is, and dates and links each one. It reports; it does not recommend. Rankings on Peptifact follow the published criteria and are never sold; how brands appear on this site is set out on our disclosure page.
What it is, and its status
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a protein in human gastric juice. It has no FDA approval, no approved label and no marketing authorization anywhere. PubMed's clinical-trial filter returned zero results for it on 2026-09-05. FDA's Pharmacy Compounding Advisory Committee considered it for the 503A bulks list on 2026-07-23 and voted 8 to 6, with one abstention, to recommend inclusion, against the position FDA staff had set out in the briefing materials; advisory votes do not bind FDA, and no rule has followed (FDA meeting page). BPC-157 was one of seven nominated peptide substances the committee reviewed at that two-day meeting, of which it recommended six and rejected emideltide (DSIP); what the vote does and does not change, including the rulemaking that would have to come first, is set out on our cognitive peptides page, which follows semax — another of the seven — through the same review. It is named under S0 of the 2026 WADA Prohibited List, listed by the NCAA for 2026-27, and on the DoD Prohibited Dietary Supplement Ingredients List. MuscleLedger's Wolverine-stack page counts the human evidence.
The dose table
| Source | What it states | Kind of source | Date opened and link |
|---|---|---|---|
| Human knee series, reviewed in HSS Journal 2025 | Single intra-articular injection of "2 cc of 2000 mcg/mL solution" (4 mg); 12 patients, 7 with relief beyond 6 months; no control | Retrospective case series | PMC12313605, 2026-09-05 |
| Animal studies, same review | "6 μg/kg to 20 mg/kg" by intramuscular, intravenous, intraperitoneal and oral routes; repeat dosing up to 6 weeks; no adverse necropsy findings | Preclinical | Same |
| Tucson Wellness MD | "Commonly discussed BPC-157 dosages range from 250 to 500 mcg per day"; by goal: 250–500 mcg daily for 2–6 weeks (tendon, ligament, joint), 250–750 mcg daily for 2–4 weeks (muscle recovery), 250–500 mcg once or twice daily for 4–6 weeks (gut); "there is no universally accepted human dosage" | Clinic guide | Page dated 2025-10-30 |
| FormBlends | "BPC-157 doses in research typically range from 200 to 800 mcg per day"; "250 mcg twice daily" as the most common starting protocol; 200–300 mcg daily (general), 300–500 (moderate injury), 500–800 twice daily (significant repair); cycles 4, 6–8 or 8–12 weeks with a 2–4 week break | Vendor-affiliated guide, author an RDN | Updated 2026-08-30 |
| Peptide Dosing Protocols | Low " |
Protocol site | Updated August 2026 |
Three observations. The clinic, vendor and protocol pages agree with each other to within a factor of two, which is what happens when pages copy each other, not what happens when a dose has been found. The one human data point is a different route, a different quantity and a single administration, so it neither supports nor contradicts the daily subcutaneous figures. And the animal range is so wide that any daily figure could be defended from it, which is the same as saying it defends none.
Reconstitution arithmetic as the guides state it
The guides use two vial sizes. A 5 mg vial with 2 mL of bacteriostatic water gives 2,500 mcg/mL, or 25 mcg per unit on a U-100 insulin syringe, so 250 mcg is 10 units (0.10 mL) and the vial holds 20 such portions. A 10 mg vial with 2 mL gives 5,000 mcg/mL, or 50 mcg per unit, so 250 mcg is 5 units and 500 mcg is 10 units. Our reconstitution page gives the procedure as an FDA label describes it and the arithmetic for any vial and volume; our storage page covers what the manufacturers' guides say about solutions.
Routes, as sources describe them
Subcutaneous injection is the route every clinic and vendor page describes; the human knee series used intra-articular injection; oral capsules are sold and described on the protocol and clinic pages at the same 250 to 500 mcg figures, without any human data for the oral route beyond the animal studies that included it. The HSS review notes that "select cash practices" offer intra-articular and oral formulations.
What is not known
Whether any dose does anything in a human; whether the subcutaneous figures on clinic pages have a basis beyond convention; what the dose-response, safety margin or long-term profile is; and whether the July 2026 advisory vote will become a rule. Nothing on this page changes any of that, and nothing on it is a recommendation.
Sources and dates
Opened 2026-09-05: HSS Journal 2025 systematic review (PMC12313605); Tucson Wellness MD BPC-157 guide (2025-10-30); FormBlends BPC-157 guide (updated 2026-08-30); Peptide Dosing Protocols BPC-157 page (August 2026); FDA PCAC July 2026 meeting page; the 2026 WADA Prohibited List. Corrections go to the contact page.